Additional study needed for RedHill's Crohn disease candidate

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) said another Phase III trial is "most likely to be required" to support an NDA submission to FDA for Crohn disease candidate

Read the full 284 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE